Volterrani M, Perrone V, Sangiorgi D, et al. - Among patients with heart failure (HF) managed with renin–angiotensin–aldosterone system inhibitors (RAASi), whether the risk of cardiovascular events as well as all‐cause death was higher in the presence of hyperkalaemia (HK) was determined in this retrospective cohort study. In this cohort, experts also investigated the raised risk of cardiovascular events and all‐cause mortality in HK patients with non‐optimal adherence to RAASi therapy. Administrative databases of five Italian Local Health Units were used. Prior to the assessment of hazard ratios, a propensity score matching was employed. In this real‐world study, an enhanced risk of cardiovascular events or death was observed in persons with HK, vs those without HK, in a cohort of HF patients under RAASi therapy. Moreover, an increased risk of all‐cause mortality was observed in relation to sub‐optimal adherence to RAASi therapy in HK patients.